208 related articles for article (PubMed ID: 20626408)
1. Structure-based in silico design of a high-affinity dipeptide inhibitor for novel protein drug target Shikimate kinase of Mycobacterium tuberculosis.
Kumar M; Verma S; Sharma S; Srinivasan A; Singh TP; Kaur P
Chem Biol Drug Des; 2010 Sep; 76(3):277-84. PubMed ID: 20626408
[TBL] [Abstract][Full Text] [Related]
2. Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid.
Pereira JH; de Oliveira JS; Canduri F; Dias MV; Palma MS; Basso LA; Santos DS; de Azevedo WF
Acta Crystallogr D Biol Crystallogr; 2004 Dec; 60(Pt 12 Pt 2):2310-9. PubMed ID: 15583379
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of a potent and selective small peptide inhibitor of Mycobacterium tuberculosis 6-hydroxymethyl-7, 8-dihydropteroate synthase: a computer modelling approach.
Rao GS; Kumar M
Chem Biol Drug Des; 2008 Jun; 71(6):540-5. PubMed ID: 18482337
[TBL] [Abstract][Full Text] [Related]
4. Molecular model of shikimate kinase from Mycobacterium tuberculosis.
Filgueira de Azevedo W; Canduri F; Simões de Oliveira J; Basso LA; Palma MS; Pereira JH; Santos DS
Biochem Biophys Res Commun; 2002 Jul; 295(1):142-8. PubMed ID: 12083781
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of shikimate kinase from Mycobacterium tuberculosis reveals the dynamic role of the LID domain in catalysis.
Gu Y; Reshetnikova L; Li Y; Wu Y; Yan H; Singh S; Ji X
J Mol Biol; 2002 Jun; 319(3):779-89. PubMed ID: 12054870
[TBL] [Abstract][Full Text] [Related]
6. Structure-based prediction of Mycobacterium tuberculosis shikimate kinase inhibitors by high-throughput virtual screening.
Segura-Cabrera A; Rodríguez-Pérez MA
Bioorg Med Chem Lett; 2008 Jun; 18(11):3152-7. PubMed ID: 18486472
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Interaction of shikimic acid with shikimate kinase.
Pereira JH; de Oliveira JS; Canduri F; Dias MV; Palma MS; Basso LA; de Azevedo WF; Santos DS
Biochem Biophys Res Commun; 2004 Dec; 325(1):10-7. PubMed ID: 15522194
[TBL] [Abstract][Full Text] [Related]
9. Identification of shikimate kinase inhibitors among anti-Mycobacterium tuberculosis compounds by LC-MS.
Simithy J; Reeve N; Hobrath JV; Reynolds RC; Calderón AI
Tuberculosis (Edinb); 2014 Mar; 94(2):152-8. PubMed ID: 24429106
[TBL] [Abstract][Full Text] [Related]
10. Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis.
Rajput VS; Mehra R; Kumar S; Nargotra A; Singh PP; Khan IA
Appl Microbiol Biotechnol; 2016 Jun; 100(12):5415-26. PubMed ID: 26887318
[TBL] [Abstract][Full Text] [Related]
11. A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis.
Shen H; Wang F; Zhang Y; Huang Q; Xu S; Hu H; Yue J; Wang H
FEBS J; 2009 Jan; 276(1):144-54. PubMed ID: 19032598
[TBL] [Abstract][Full Text] [Related]
12. Benzothiazole Derivative as a Novel Mycobacterium tuberculosis Shikimate Kinase Inhibitor: Identification and Elucidation of Its Allosteric Mode of Inhibition.
Mehra R; Rajput VS; Gupta M; Chib R; Kumar A; Wazir P; Khan IA; Nargotra A
J Chem Inf Model; 2016 May; 56(5):930-40. PubMed ID: 27149193
[TBL] [Abstract][Full Text] [Related]
13. Structural studies of shikimate 5-dehydrogenase from Mycobacterium tuberculosis.
Arcuri HA; Borges JC; Fonseca IO; Pereira JH; Neto JR; Basso LA; Santos DS; de Azevedo WF
Proteins; 2008 Aug; 72(2):720-30. PubMed ID: 18260104
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterium tuberculosis shikimate kinase inhibitors: design and simulation studies of the catalytic turnover.
Blanco B; Prado V; Lence E; Otero JM; Garcia-Doval C; van Raaij MJ; Llamas-Saiz AL; Lamb H; Hawkins AR; González-Bello C
J Am Chem Soc; 2013 Aug; 135(33):12366-76. PubMed ID: 23889343
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
Subba Rao G; Vijayakrishnan R; Kumar M
Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
[TBL] [Abstract][Full Text] [Related]
16. Shikimate kinase (EC 2.7.1.71) from Mycobacterium tuberculosis: kinetics and structural dynamics of a potential molecular target for drug development.
Saidemberg DM; Passarelli AW; Rodrigues AV; Basso LA; Santos DS; Palma MS
Curr Med Chem; 2011; 18(9):1299-310. PubMed ID: 21366533
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of phosphoryl transfer catalyzed by shikimate kinase from Mycobacterium tuberculosis.
Hartmann MD; Bourenkov GP; Oberschall A; Strizhov N; Bartunik HD
J Mol Biol; 2006 Dec; 364(3):411-23. PubMed ID: 17020768
[TBL] [Abstract][Full Text] [Related]
18. Cloning and overexpression in soluble form of functional shikimate kinase and 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pinto CA; Basso LA; Santos DS
Protein Expr Purif; 2001 Aug; 22(3):430-5. PubMed ID: 11483005
[TBL] [Abstract][Full Text] [Related]
19. Structure-aided design of inhibitors of Mycobacterium tuberculosis thymidylate kinase.
Van Calenbergh S
Verh K Acad Geneeskd Belg; 2006; 68(4):223-48. PubMed ID: 17214439
[TBL] [Abstract][Full Text] [Related]
20. Crystallographic studies of shikimate binding and induced conformational changes in Mycobacterium tuberculosis shikimate kinase.
Dhaliwal B; Nichols CE; Ren J; Lockyer M; Charles I; Hawkins AR; Stammers DK
FEBS Lett; 2004 Sep; 574(1-3):49-54. PubMed ID: 15358538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
